> **Verfora acquires majority stake in distribution partner Qpharma - Galenica.com**

> With Qpharma, Verfora is gaining an established Polish pharmaceutical distributor with a strong distribution platform in Central and Eastern Europe.

- Language: en
- Last Modified: 2026-11-18
- Source: <https://www.galenica.com/en/storyhub/eqs/86792312-b676-44cf-85a8-3274a5ad078e.php>
- Alternate (fr): <https://www.galenica.com/fr/storyhub/eqs/86792312-b676-44cf-85a8-3274a5ad078e.php>
- Alternate (de): <https://www.galenica.com/de/storyhub/eqs/86792312-b676-44cf-85a8-3274a5ad078e.php>
- Search: <https://www.galenica.com/en/search/index.php?searchTerm={search_term_string}>

---

Press release  2026/11/18

# Verfora acquires majority stake in distribution partner Qpharma

- With Qpharma, Verfora is gaining an established Polish pharmaceutical distributor with a strong distribution platform in Central and Eastern Europe.
- Qpharma already distributes Verfora products.
- The acquisition expands Verfora’s distribution base and creates further opportunities for development in Central and Eastern Europe.

Verfora is acquiring a majority stake in the Polish pharmaceutical distributor Qpharma. With the acquisition of 51% of the shares, Verfora is expanding its distribution network to include a long-standing distribution partner and thus an established distribution platform. At the same time, the company is gaining an important partner along its own value chain and thus, alongside Austria, a second distribution network in Europe. The combination of strong brands, marketing expertise and local distribution know-how creates additional development opportunities for its existing consumer healthcare business.

### Established distribution platform

Qpharma is a family-run company based in Poland that has been active in the healthcare market for over 20 years and generated sales in the low double-digit million euro range. The company specialises in marketing, promotion and distribution of prescription-only drugs, OTC products and dietary supplements. Qpharma has exclusive distribution rights for various brands in Poland, the Czech Republic and Slovakia.

Qpharma has built up an established market position in Eastern Europe and has long-standing customer relationships as well as extensive experience in marketing and distribution of healthcare products. The company has been working with Verfora for many years and is responsible for the distribution of various Verfora products, including Perskindol in Poland and the Czech Republic and, since 2025, Padma products in Poland.

### Acquisition of a long-standing partner

The acquisition brings together Verfora’s brand and marketing expertise with Qpharma’s established distribution platform and expands Verfora’s value chain. Qpharma’s attractive distribution licences also offer further development potential. Following the acquisition, Qpharma will continue to be managed by the current CEO, Zbyszek Czop, and developed together with Verfora.

“Qpharma has been an important partner for our brands for many years with an excellent understanding of our products, quality standards and its customers’ needs. With this acquisition, we are further developing a successful collaboration and creating the conditions to make even better use of our combined potential,” says Stefan Wälti, CEO of Verfora.

Completion of the transaction is subject to regulatory approvals. The parties have agreed not to disclose the sale price.

[Galenica strengthens its consumer healthcare business](https://nwr.eqs-cockpit.com/fncls2.ssx?fn=redirect&u=d37b3e7bb06e541f1f34206ab019ba76&inline_display=1)

Share post:

[back](https://www.galenica.com/en/storyhub/index.php)

## Media inquiries & contact

Do you have questions about Galenica?
Get in touch with us.

[Media inquiries & contact](https://www.galenica.com/en/medien-news/medienkontakte.php)

## You might also be interested in this

Press releases

2026/10/26

#### Galenica successfully places a bond of over CHF 200 million

Today, Galenica successfully placed a fixed rate bond of over CHF 200 million. The bond has a term of 4 years and an annual coupon of 1.2775%.

[Galenica successfully places a bond of over CHF 200 million](https://www.galenica.com/en/storyhub/eqs/216bfdff-51da-47a5-b9fd-a0fb4222acf2.php)

Ad hoc announcements

2026/10/22

#### Galenica continues growth trajectory and confirms outlook for 2026

Galenica increases sales by 5.7% to CHF 3,172.0 million in the first nine months of 2026. The pharmacy business and home care are key contributors to growth.

[Galenica continues growth trajectory and confirms outlook for 2026](https://www.galenica.com/en/storyhub/eqs/75d2d9ff-4b40-4a24-8f9a-71d7d8e85670.php)

2026/09/17

#### Five football pitches full of medication – and one system for emergencies

Millions of packs of medicines are stored in Burgdorf. Some of them are intended for the moment when the market can no longer guarantee supply. How this compulsory stock works and is drawn upon, why it is far from being a dusty emergency reserve, and what role the Galenica network company Alloga plays in supplying Switzerland.

[Five football pitches full of medication – and one system for emergencies](https://www.galenica.com/en/news/entries/20260915-6827872869-news.php)

2026/09/01

#### A new gem joins the network: Galenica acquires Bären Apotheke am Zytglogge

The long-established Bären Apotheke am Zytglogge has been part of Bern’s cityscape for generations. Since 1 September 2026, it has been part of the Galenica network and continues to operate under the name “Bären Vita Zytglogge” with a new concept. This preserves a piece of Bern’s history while opening up new prospects for its future.

[A new gem joins the network: Galenica acquires Bären Apotheke am Zytglogge](https://www.galenica.com/en/news/entries/20260831-1530729059-news.php)

2026/08/31

#### Creating New Spaces in Harmony with Our Culture

The world of work is constantly evolving, and Galenica is evolving with it. As part of our transformation, we are actively shaping the future. This is reflected not only in the way we collaborate, but also in the environments in which we work.

[Creating New Spaces in Harmony with Our Culture](https://www.galenica.com/en/news/entries/20260828-4185621035-news.php)

Ad hoc announcements

2026/08/06

#### Galenica maintains its track record of consistent growth

Galenica increases sales by 7.1% to CHF 2,136.5 million in the first half of 2026. Adjusted<sup>1</sup> EBIT increases by 7.1% to CHF 117.7 million.

[Galenica maintains its track record of consistent growth](https://www.galenica.com/en/storyhub/eqs/56b03300-1d96-40ad-8ba5-2aa0e5bb109b.php)

2026/06/30

#### Change in the Executive Committee of Labor Team

Alain M. Cahen will step down as CEO of Labor Team at the end of June 2026 and will also leave the Executive Committee. COO Thomas Brinkmann will take over on an interim basis.

[Change in the Executive Committee of Labor Team](https://www.galenica.com/en/news/entries/20260630-1601920926-news.php)

Video

2026/06/18

#### Coordinated basic care: From pilot projects to system solutions

Collaboration between different healthcare providers is already being tested in numerous pilot projects. One recent example is the Baselland supply model, which also involves participation from pharmacies in the Galenica network. The task going forward is to develop these approaches systematically and translate them into sustainable, broad-based system solutions. Daniele Madonna, Chief Pharmacies Category Management & Health Services, called for this step at this year’s Healthcare Professionals Initiative on 5 June 2026.

[Coordinated basic care: From pilot projects to system solutions](https://www.galenica.com/en/news/entries/20260617-4349880772-news.php)

Video

2026/06/01

#### Sun Store Renens: First pharmacy in Western Switzerland to introduce the new concept

With the redesigned Sun Store pharmacy in Renens (VD), the first pharmacy in Western Switzerland is opening with a completely new concept. It places a strong focus on personalised advice, healthcare services and the overall customer experience. The aim is to further improve people’s access to low-threshold primary care services.

[Sun Store Renens: First pharmacy in Western Switzerland to introduce the new concept](https://www.galenica.com/en/news/entries/20260428-7147085906-news.php)

Ad hoc announcements

2026/05/28

#### Galenica posts strong sales growth in a challenging market environment

Galenica achieves sales growth of 7.3% to CHF 1,409.7 million in the first four months of 2026. The main driver is strong growth in the pharmacy business and wholesale.

[Galenica posts strong sales growth in a challenging market environment](https://www.galenica.com/en/storyhub/eqs/0cdc267f-ff8c-44e0-9109-47b20a30a9e4.php)